Montrate (Montelukast) is primarily used in clinical settings where patients require long-term supportive relief to manage conditions characterized by persistent inflammation and airway sensitivity. Its therapeutic application focuses on the daily prevention of symptoms, generally contributing to maintaining functional stability across key respiratory and allergic domains. The medication is used for several major therapeutic areas.

The core indications involve chronic asthma maintenance, relief of symptoms from seasonal and perennial allergic rhinitis, and the preventive management of breathing difficulty triggered by exercise.

Daily Maintenance for Chronic Asthma

This domain covers the treatment of recurring asthma symptoms, including wheezing, chest tightness, and persistent coughing. Montrate is generally used to provide consistent, daily support that helps ease the overall burden of these symptoms, contributing to a more stable experience of breathing and may support a reduction in the overall symptom load.

Relief from Seasonal and Perennial Nasal Allergies

The medication helps address the symptom cluster of allergic rhinitis, such as frequent sneezing, runny nose, and problematic nasal congestion, whether the symptoms are seasonal or present year-round. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, especially in situations where patients require additional symptomatic support for their allergies.

Prophylaxis of Exercise-Induced Breathing Difficulty

This use focuses on the preventive management of predictable airway narrowing triggered by physical exertion. Applied in these specific situations, Montrate supports the patient during difficult episodes by easing distress related to physical exertion, offering supportive assistance that contributes to improved day-to-day comfort and assists with maintaining functional stability.

Quick Fact: Relief for Inflammatory Symptoms Montrate is relevant for easing symptoms related to heightened physiological activity in the airways, and helps improve day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Montrate (Montelukast) eligibility is governed by official age thresholds and specific clinical exclusions detailed in regulatory documents.

Contraindications and Exclusions

Age and Condition Rules

Use is allowed for adults and adolescents 15 years and older for all main indications. Eligibility for children is complex, with specific minimum age cutoffs:

• Pediatric Use: The medication is approved for asthma and allergic rhinitis in patients as young as 2 years of age. Use for perennial allergic rhinitis may begin at 6 months, but effectiveness is not established for infants under 12 months for asthma, or under 6 years for preventing exercise-induced breathing difficulty.
• Severe Organ Impairment: No data are available for Montelukast use in patients with severe hepatic impairment. No dose adjustment is needed for older adults, renal insufficiency, or mild-to-moderate hepatic impairment.
• Pregnancy and Lactation: Use during pregnancy and breastfeeding is classified as conditional, permissible only if considered clearly essential by the prescribing physician.

Interactions with other medicines and products

Montrate (Montelukast) interactions are primarily defined by its clearance through metabolic pathways. Co-administration with Gemfibrozil, an inhibitor of the CYP2C8 and CYP2C9 enzymes, is documented to cause a significant increase in Montelukast systemic exposure (AUC) by approximately 4.4-fold. Conversely, co-administration with strong enzyme inducers, such as Phenobarbital or Rifampin, is associated with a decrease in Montelukast exposure by about 40%.

Despite these pharmacokinetic findings, Montelukast does not cause clinically important effects on the pharmacokinetics of several other commonly co-administered medicines, including Theophylline, Warfarin, and Digoxin.

The official labeling also includes specific pharmacodynamic restrictions. Montelukast is not to be abruptly substituted for inhaled or oral corticosteroids. Patients with a known sensitivity to Aspirin or Non-Steroidal Anti-Inflammatory Agents (NSAIDs) must continue to avoid these substances while taking Montelukast.

For the oral granule formulation, administration with a high fat meal is documented to reduce the drug’s peak plasma concentration ( Cmax) by 35%. A population-specific note identifies that patients with mild-to-moderate hepatic insufficiency have an approximate 41% higher mean AUC, reflecting reduced metabolism.

Montrate is a small molecule that acts as a selective inhibitor of the lysosomal cysteine protease Cathepsin K. The molecule achieves its pharmacodynamic effect by specifically binding to the active catalytic site of the enzyme. Cathepsin K is primarily expressed and utilized by osteoclasts to degrade type I collagen and other components of the organic bone matrix during the process of bone resorption. By limiting the proteolytic activity of Cathepsin K within the resorption lacunae of osteoclasts, Montrate modulates the cellular rate of matrix degradation. This action results in a reduction in the overall rate of bone resorption, which is measurable as a net decrease in the release of degradation products from the bone matrix. The mechanism demonstrates high selectivity for Cathepsin K relative to other related cysteine proteases.

The medication Montrate (Montelukast) is administered exclusively via the oral route and is available in three distinct formulations: film-coated tablets (10 mg), chewable tablets (5 mg and 4 mg), and oral granules (4 mg). The treatment is designed for once-daily use in long-term treatment protocols.

For chronic indications such as maintenance therapy for asthma and perennial allergic rhinitis, the dose should be taken consistently in the evening. The standard adult and adolescent (age 15 years and older) dose is 10 mg once daily. Pediatric dosing is age-tiered: 5 mg for children 6 to 14 years, and 4 mg for children 2 to 5 years and 6 to 23 months (for applicable uses).

Administration instructions vary by form. Chewable tablets must be fully chewed before swallowing, while both tablets and chewable tablets may be taken with or without food. Oral granules must be administered within 15 minutes of opening the sachet. Granules can be mixed with a spoonful of cold or room-temperature soft food, formula, or breast milk, but must not be dissolved in other liquids.

For the prevention of exercise-induced bronchoconstriction (EIB), a separate 10 mg dose may be taken at least two hours before activity. It is specified that if a patient is already taking a daily dose for chronic maintenance, an additional dose must not be taken for EIB prophylaxis within the same 24-hour period. No dosage adjustments are typically required for older adults or patients with renal or mild-to-moderate hepatic impairment. The medicine is not used to treat acute asthma episodes.

Montrate: Recent Clinical Evidence

Montrate (isosorbide mononitrate) is an anti-anginal medication with a well-established history for the prevention of chest pain (angina pectoris) due to coronary artery disease. Recent clinical studies continue to confirm its effectiveness in reducing the frequency of angina episodes and improving exercise tolerance in patients with chronic stable angina.

Efficacy in Chronic Stable Angina

Clinical trials, including randomized, controlled studies, have shown that extended-release formulations of isosorbide mononitrate can significantly increase the duration of exercise before the onset of angina and before experiencing a specific degree of ST-segment depression on an electrocardiogram, compared to a placebo. This sustained effect is vital for long-term management.

• Studies demonstrate a reduction in the average number of angina attacks per week.
• The drug's benefit on exercise tolerance is generally maintained over the course of extended treatment, provided an appropriate daily "nitrate-free interval" is maintained to prevent the development of nitrate tolerance.

Tolerability and Safety Profile

Isosorbide mononitrate is typically well-tolerated. The most common side effect reported in clinical practice and trials is headache, which is often related to the drug's vasodilating properties and may lessen with continued use.

Less common, but serious, adverse effects are related to the drug's effect on blood pressure. These effects are why the medication is contraindicated for use with certain other drugs, such as phosphodiesterase inhibitors (used for erectile dysfunction or pulmonary hypertension), as the combination can lead to severe and dangerous drops in blood pressure (hypotension).

These findings reinforce Montrate's role as a reliable, long-term therapeutic option for preventing angina, with its use guided by careful patient selection and monitoring for drug interactions.

Common questions about Montrate (FAQ)

Q: Is Montrate the brand name or the generic name?

Montrate is described as the brand name used for this specific formulation. The active ingredient within this medicine is Montelukast. Official sources confirm that the active ingredient itself is widely available in generic form.

Q: Is there a generic version of Montrate available?

Yes, the active ingredient found in Montrate, Montelukast, is widely available as a generic medicine. The availability of a generic version means that the active ingredient must meet the same standards as the brand-name medicine for public use.

Q: What is the risk of developing a serious side effect from Montrate?

Serious side effects, such as Churg-Strauss Syndrome or suicidal thoughts and behaviour, are documented in the official safety information. These events are classified as Very Rare, meaning they affect less than 1 in 10,000 people based on clinical trial data and post-marketing reports. The full list of potential side effects is detailed in the official patient information leaflet.

Q: Does Montrate have a Black Box Warning?

Yes, official U.S. regulatory labeling for Montelukast includes a Boxed Warning, which is the strongest type of warning the FDA requires. This warning highlights the potential for serious neuropsychiatric events, including suicidal thoughts and actions. Official documentation notes that vigilance for any changes in behavior or mood is warranted.

Q: Can I take pain relievers (like ibuprofen) with Montrate?

Regulatory studies have shown that Montelukast does not cause clinically important changes in the way some other commonly co-administered medicines work. However, official warnings describe that patients with a known sensitivity to Aspirin or other Non-Steroidal Anti-Inflammatory Agents (NSAIDs) are instructed to continue avoiding these substances.

Q: Is Montrate considered a controlled substance?

No. Montrate, which contains the active ingredient Montelukast, is not classified as a controlled substance by U.S. regulatory bodies.

Q: What is the FDA classification or regulatory status of Montrate?

Montrate (Montelukast) is a prescription-only medication. It is pharmacologically classified as a Leukotriene Receptor Antagonist (LTRA), which means it works by blocking inflammatory mediators in the body.

Q: How quickly can one expect to notice an effect after starting Montrate?

Official information on the medicine's kinetics shows that the active ingredient, Montelukast, typically reaches its peak concentration in the bloodstream approximately 2 to 4 hours after the tablet or chewable tablet is taken. This measurement indicates the time when the maximum concentration of the medicine is typically reached in the body.

Q: How long does the effect of Montrate last after taking it?

The average elimination half-life—the time it takes for half of the dose to be cleared—is approximately 2.7 to 5.5 hours following a single dose. The average elimination half-life of the active ingredient is a pharmacokinetic measurement related to how quickly the medicine is cleared from the body.

Q: What is the timeframe for a typical course of Montrate treatment?

Official documentation describes the medicine as being for the long-term treatment and maintenance therapy of chronic conditions, such as asthma and allergic rhinitis. It is intended for consistent daily use over an extended period.

Q: Is Montrate safe to take with alcohol?

Regulatory documents do not list a direct interaction between this medication and alcohol. However, adverse reports of rare hepatitis (liver injury) have been documented, and official safety notes mention the involvement of patients with certain pre-existing risk factors.

Q: Can I take Montrate if I have high blood pressure?

Regulatory documents do not list high blood pressure (hypertension) as a contraindication or a condition that requires a specific dosage adjustment for Montrate (Montelukast).

Q: Does Montrate interact with birth control pills?

Regulatory studies on drug interactions have shown that Montelukast does not cause clinically important effects on the pharmacokinetics of commonly co-administered medicines, including oral contraceptives.

Q: Are there any dietary restrictions or foods to avoid while taking Montrate?

Official patient information states that a normal diet should be continued unless otherwise advised. Specific instructions exist that a high-fat meal may reduce the absorption of the oral granule form. The chewable tablets contain phenylalanine, which is a component that requires special consideration for patients with Phenylketonuria (PKU).

Q: Is it normal to feel tired when first starting Montrate?

Somnolence (drowsiness or tiredness) is documented in official safety information as an uncommon side effect. This effect is recognized in official regulatory adverse reaction lists under the nervous system disorders.

Q: How does Montrate affect sleep patterns?

Official documents list various sleep disorders as documented adverse reactions under the Psychiatric disorders class. These can include reports of nightmares, insomnia (difficulty sleeping), and abnormal dreams.

Q: Is it true that Montrate may cause changes in mood?

Yes, changes in mood and behavior are recognized adverse reactions listed in the official safety information. These effects fall under the Psychiatric disorders System-Organ Class and include agitation, anxiety, and depression.

Q: Does Montrate require special monitoring like blood tests?

Regulatory documents do not typically specify routine laboratory monitoring for Montrate itself. However, regulatory documents do note that vigilance for neuropsychiatric symptoms and the potential for rare hepatitis (liver injury) is warranted.

Q: Is Montrate appropriate for elderly patients?

Official instructions state that dosage adjustments are not typically required for older adult patients (over 65 years of age). Official instructions indicate that no routine dosage adjustments are typically necessary for this age group.

Q: What research is currently being done on Montrate?

Official government clinical trial registries, such as those maintained by the NIH and EMA, list ongoing research studies for the active ingredient, Montelukast. These studies cover various indications and continued monitoring of the medicine's safety profile.

Q: Are the clinical trials for Montrate still ongoing or completed?

Regulatory databases for clinical trials indicate that studies for the active ingredient, Montelukast, are both completed and currently ongoing for various indications. These trials are conducted to gather and monitor data regarding the medication's use and safety profile.

Q: Where can I find the full package insert or patient information leaflet for Montrate?

The full Prescribing Information (also called the package insert) and the Patient Information Leaflet are available on official government drug regulatory websites. Examples include official government drug repositories like the FDA's DailyMed or the NIH's MedlinePlus.

Q: What should I do if I think I'm having an allergic reaction to Montrate?

Official documents list hypersensitivity reactions (including swelling of the face, lips, tongue, and/or throat) as an uncommon adverse effect. This type of reaction is recognized as serious, and patients are advised to seek care from a healthcare provider.

Q: Is it necessary to taper off Montrate when stopping the treatment?

Regulatory documents state that Montrate must not be abruptly substituted for inhaled or oral corticosteroids. However, no specific tapering instruction is provided in the official labeling for discontinuation of Montrate alone.

Q: Does Montrate affect my ability to drive or operate machinery?

Official documents state that Montelukast is not expected to affect the ability to drive or operate machinery. However, due to rare reports of dizziness or drowsiness, the documents note that patients should monitor their individual response, particularly for these rare effects.

Q: Does the effectiveness of Montrate decrease over time?

Clinical trials supporting the long-term use of Montrate demonstrated that the medicine's clinical benefits were generally maintained during the course of extended treatment for its approved indications.

Q: What happens if I take Montrate with grapefruit juice?

Regulatory documents on drug interactions do not list an interaction between Montrate (Montelukast) and grapefruit juice.

Q: Is Montrate known to interact with herbal supplements?

Comprehensive patient information provided by regulatory bodies advises caution regarding complementary medicines and herbal remedies. This is because such products are not typically tested for their potential to interact with Montrate.

Q: Is it true that Montrate has been studied for effects on the liver?

Yes. Studies have been conducted to examine the medicine's behavior in patients with mild-to-moderate hepatic insufficiency (liver problems). Furthermore, regulatory safety documents list rare adverse reports of hepatitis (liver injury).

Q: What kind of information is considered necessary to discuss with a healthcare provider before starting Montrate?

Regulatory warnings and precautions highlight several key points for discussion. This includes any history of neuropsychiatric symptoms, known sensitivity to Aspirin or NSAIDs, and whether the patient is pregnant or breastfeeding.

Q: Is Montrate's efficacy supported by peer-reviewed studies?

Regulatory approval for the medication is based on data from clinical trials. The findings from these trials are typically published and contribute to the body of peer-reviewed evidence supporting the medication's approved uses.

Q: What is the possibility of dependency or withdrawal symptoms with Montrate?

Official regulatory documents do not indicate that Montrate (Montelukast) is associated with drug dependency or a defined withdrawal syndrome.

Q: Does my age affect the way Montrate works?

Age is a factor considered in the official prescribing information. Different dosage recommendations are provided for specific pediatric age groups, reflecting the consideration of age-dependent pharmacokinetics (how the body handles the drug) and safety data.

Q: Can I take Montrate if I have a history of kidney problems?

According to the official instructions, dosage adjustments are not typically required for patients with renal (kidney) insufficiency.

Q: How is the drug stability of Montrate described in official documents?

Official regulatory information describes the drug as requiring storage at Controlled Room Temperature and specifies that the packaging must protect the medicine from both moisture and light to maintain its stability and effectiveness.

How to Store and Dispose of Montrate?

Montrate (montelukast sodium) must be stored strictly according to its official labeled requirements to maintain its stability and effectiveness. The product should be kept at Controlled Room Temperature, which is officially defined as 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F).

Protection from moisture and light is essential, which means the medication must be stored in its original, protective packaging. As with all medications, Montrate must be stored out of the sight and reach of children.

For disposal, follow the specific instructions on the prescription drug labeling or patient information. If no instructions are provided, the FDA generally recommends using a community drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown in the household trash. Do not flush Montrate down the toilet or pour it down a drain unless explicitly instructed by the labeling.